Preview

Amicus Therapeutics Case Study

Satisfactory Essays
Open Document
Open Document
346 Words
Grammar
Grammar
Plagiarism
Plagiarism
Writing
Writing
Score
Score
Amicus Therapeutics Case Study
News of the latest advancements in strategies and treatment against many rare diseases comes out of the pharmaceutical company named Amicus Therapeutics. Based in Cranbury, New Jersey, with a second research facility in Southern California, the company is making gains in the pharmaceutical industry on the heel of announcements that the Food and Drug Administration (FDA) is planning to accept a New Drug Application (NDA) for the new drug Migalastat which was developed by Amicus Therapeutics.

An oral precision medicine, Migalasta will be the latest in an arsenal of treatments against Fabry disease. Industry followers of Amicus Therapeutics anxiously await its latest submission during the fourth quarter of 2017.

Reason For New Hope

Chief Medical Officer of Amicus
…show more content…
alone battle Fabry Disease; moreover, Amicus Therapeutics believes that this sets a sound stage for further development of the new drug Migalastat.

In further statements, Jay Barth went on to say that data on Migalastat demonstrates that Amicus Therapeutics is data-driven and science-based and a formidable force to contend with in the pharmaceutical industry.

About Amicus Therapeutics

As a biotechnology company, Amicus Therapeutics is on the forefront of making its mark dealing globally with therapies for rare diseases. Through various initiatives, they have demonstrated a passion for developing medicines and technologies to help people with the rare diseases including: Fabry diseases, Epidermolysis Bullosa and connective skin disorders as well as Pompe disease.

As such, Migalastat is the first approved medicine for Fabry disease and the stellar drug from Amicus Therapeutics.

Their mission is using biotechnology to heal rare diseases, and it has an extensive trajectory of collaborating with the health care industry in general. This includes health care practitioners, individual patients, caregivers and organizations in the rare disease

You May Also Find These Documents Helpful

  • Powerful Essays

    The Medicines Company

    • 868 Words
    • 5 Pages

    The Medicines Company Case Write-Up: Terence Cho, Felipe Duarte, Aleks Loiko, Robert Shaw, and James Wang…

    • 868 Words
    • 5 Pages
    Powerful Essays
  • Good Essays

    Mism Phs Case Study

    • 610 Words
    • 3 Pages

    | * Patients can save their time * Target more specific therapies for patients * It has the low-cost options among potential treatment strategies…

    • 610 Words
    • 3 Pages
    Good Essays
  • Good Essays

    If gene therapy has been approved in the US, what is it being used to treat?…

    • 369 Words
    • 1 Page
    Good Essays
  • Good Essays

    Stem Cell Research Foundation. "Stem Cells Will Soon Provide Cures for Many Diseases." Detroit: Greenhaven Press, 2007.…

    • 1188 Words
    • 5 Pages
    Good Essays
  • Powerful Essays

    Merck & Co. Inc. is one of the world’s largest pharmaceutical companies in the world for producers of prescription drugs. Merck had sales of 1.98 billion and net income of 307 million in 1978 and continues to steadily rise. Merck invested hundreds of millions of dollars each year in research and allocate the funds amongst various projects. On average it would take approximately 12 years and 200 million dollars to bring a new drug into the market. Many potential drugs offered little chance of financial returns, as some diseases were so rare that treatment could never be priced high enough for the company to recoup the investment. Congress sought to encourage drug companies to further research on rare diseases by proposing tax benefits and seven-year exclusive marketing rights if they manufactured drugs for diseases afflicting fewer than 200,000 Americans. River blindness, also known as “onchocerciasis” is a disease found in over 35 developing countries throughout the Third World. The cause of the disease came from parasitic worm that were carried by black flies. In 1978, the World Health Organization (WHO) estimated that approximately 340,000 people were blind because of this disease and 18 million or more were infected with the parasite, but not many showed symptoms. Merck researchers have found a compound called ‘Ivermectin’, which has proven to have an astonishing effect against wide range of parasites in animals. Dr. Campbell proposed the idea to have the compound formulated to work against human parasite, but the success rate was very low. Even if the drug was successful attained, the economy viability would be nil and no U.S. or international program would create any incentives for Merck to develop drugs for diseases like river blindness.…

    • 829 Words
    • 3 Pages
    Powerful Essays
  • Better Essays

    Poncin, Y., Denis, G. S., McGuire, J., & Scahill, L. (2007). Drug and non-drug treatments of…

    • 5241 Words
    • 21 Pages
    Better Essays
  • Good Essays

    In recent years, there has been an expansion of product development activities for colorectal cancer through a number of new public-private partnerships (PPPs). However, there is a lack of credible drug leads to feed the development pipeline of these PPPs and there is a great need for new drug discovery initiatives to produce such leads. There is a need to go beyond lead discovery and identify drug candidates that can be further developed.…

    • 1870 Words
    • 8 Pages
    Good Essays
  • Satisfactory Essays

    river blindness

    • 303 Words
    • 2 Pages

    Merck is a pharmaceutical company located in New Jersey which is known for productivity of research and development effort. In the mid of 1980 in veterinarian drug unit, Dr William Campbell note a marked genetic similarity between the microfilariae found in horses which had a connection with microfilariae lead to blindness of human. However, to do the human testing, there were both moral and financial problems.…

    • 303 Words
    • 2 Pages
    Satisfactory Essays
  • Powerful Essays

    Considered a leader in the biotechnology industry, Genzyme has come a long way since its inception as a supplier of basic chemicals and reagents in 1981. As a leader in the development of orphan drugs, Genzyme realized revenues of almost $4B in 2007. Greater than 30% of its revenue in 2007 is attributed to the sales of drugs that target orphan diseases, such as Cerezyme, a novel Genzyme drug used to treat Gaucher disease. Due to the lack of previous research on orphan diseases, the development of drugs in this area is costly, requiring Genzyme to charge outrageous sums of money for treatment. For example, Cerezyme costs $50-200K per year per patient, an amount of money that is often well beyond the reach of patients suffering from Gaucher. To bridge the gap between the cost of Cerezyme and the patient’s ability to pay, Genzyme has to rely on government agencies to shoulder the cost for its citizens. Understanding that government subsidies are crucial to realizing any profit with their orphan disease drugs, Genzyme has developed strong relationships with NGO’s and government health-care agencies to create a culture of caring at Genzyme that they leverage to convince governments around the world to pay for patient medication. With such a large piece of their revenue being generated by these drugs, Genzyme has vested interest in ensuring this extremely profitable side of their business is positioned strongly in the global market. Thus, Genzyme has been able to generate revenue by increasing the willingness of their customers, mainly government agencies, to pay.…

    • 1889 Words
    • 8 Pages
    Powerful Essays
  • Satisfactory Essays

    It was the world's first combination of an alpha agonist and a bet blocker (two types of drugs) in one bottle for the treatment of this disease.…

    • 312 Words
    • 2 Pages
    Satisfactory Essays
  • Satisfactory Essays

    Essay2

    • 328 Words
    • 2 Pages

    4. Phase I clinical studies study the effect of a drug on patients with the disease.…

    • 328 Words
    • 2 Pages
    Satisfactory Essays
  • Best Essays

    Roche: Cancer and Swiss Francs

    • 58506 Words
    • 235 Pages

    The FDA approved Erivedge (vismodegib), a first-in-class Hedgehog Pathway Inhibitor for adults with advanced basal cell carcinoma. The FDA approved Perjeta (pertuzumab)…

    • 58506 Words
    • 235 Pages
    Best Essays
  • Powerful Essays

    We expect a similar scenario to unfold in the treatment of Recurrent/ Refractory MDS (RR-MDS, High-Risk MDS), and Relapsed/ Refractory AML (R/R AML). Innovative approach to treating unmet need has been handsomely rewarded in the past through in-licensing or outright acquisition of the mature/nascent product/innovator company at a premium. The report provides an overview of the approved therapies for RRMM, NDMM, AML, MDS, unmet need and limitations of the current SOC for relapsed and refractory pts. The report highlights the competition and commercial opportunity in pursuing these therapy areas – Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them…

    • 712 Words
    • 3 Pages
    Powerful Essays
  • Good Essays

    Case Study Of Orencia

    • 981 Words
    • 4 Pages

    We will review the financial activity of launching Orencia as a pharmacological treatment in the reduction of symptoms associated with Scleroderma. The financial activity regarding the launch expenditures are listed on table 1. A yearly activity sheet is provided to assess the stability of the product to our board of directors. An income statement, market share, and profitability ratio are listed on table 1. The ratio will examine the product positioning in the market, based on population and pricing. Pharmaceuticals account for 15 percent of health care spending, but the cost of orphan drugs and other biologics are rising 20 percent to 25 percent a year(Managedcarearticle). The Orphan Drug Act of 1983, documents the ability to obtain…

    • 981 Words
    • 4 Pages
    Good Essays
  • Satisfactory Essays

    Case Study Merck

    • 707 Words
    • 3 Pages

    Even if the drug has a small percent of curing river blindness, they should consider the people that are affected by the disease and the conditions that they live in. In the case, it states that researching could take years, but if one life is saved from the medication, I feel that it would be a success because I do not feel that a company should put a value on a human life. Since the river blindness occurs in an underdeveloped part of the world where the occupants are deprived of basic necessities, the decision of developing the drug becomes a question of philanthropy than a question of profit.…

    • 707 Words
    • 3 Pages
    Satisfactory Essays